	Rheumatoid arthritis
Retrospective study
Infliximab
EULAR response
	disease activity
infliximab therapy
clinical efficacy
adverse events
demographic factors
response criteria
infliximab
discontinuation
therapy
clinical response
adverse reactions
patients
week
CRP
disease
DAS 28
factors
study
response
secondary insufficiency
treatment
RA management group
Younger age
retrospective clinical study
disease duration
EULAR criteria
dose
Japan
moderate
low activity
MTX
remission
notable efficacy
global VAS
age
low
high

